Amycretin
About
About Amycretin
Amycretin is a unimolecular fusion peptide combining GLP-1 receptor agonism with amylin receptor agonism in a single molecule, developed by Novo Nordisk as the next evolution beyond semaglutide. Phase I data showed extraordinary weight loss of approximately 13% over just 12 weeks — suggesting potential for 25%+ reductions at full treatment duration. It represents the first clinically advanced GLP-1/amylin combination in a single molecular entity.
Science
Mechanism of Action
Simultaneously activates GLP-1 receptors to suppress appetite and slow gastric emptying, and amylin receptors in the area postrema and hypothalamus to independently reduce food intake and body weight through complementary and additive satiety pathways.
Dosing
Typical Protocol
Weekly subcutaneous injection; Phase I doses not publicly disclosed; Phase II ongoing as of 2025.
⚠ Protocol information is for educational purposes only. Dosing must be determined by a licensed physician based on individual health status and goals.
Regulatory
Legal Status in 2026
This compound occupies a regulatory grey area in 2026. It is neither explicitly FDA-approved nor clearly illegal for personal use, but it lacks formal clinical approval and may not be legally sold for human use in all contexts. Proceed with caution: source quality is variable, and regulatory status can change. Always consult a physician.
Evidence
Evidence Tier
Evidence from randomized controlled trials (RCTs) or large observational studies in humans. This is the gold standard — effects have been measured in controlled conditions and results are peer-reviewed and reproducible.
Find a Verified Provider
See which Vial-verified providers offer Amycretin — with trust scores, legal credentials, and pricing transparency.